Menu Close Call 1-800-CEDARS-1 toggle search form Close
COVID-19 (Coronavirus)
Information for Patients & Visitors

Stanley C. Jordan, MD

Director, HLA and Transplant Immunology Laboratory, Comprehensive Transplant Center

Director, Division of Nephrology

Director, Nephrology

Medical Director, Kidney Transplant Program, Comprehensive Transplant Center

Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory

Medical Director, Kidney Transplant Program

Professor, Medicine

Stanley C. Jordan, MD

Comprehensive Transplant Center
8900 Beverly Blvd
Los Angeles, CA
90048

Phone:

310-423-2641

Fax:

310-423-0234

Stanley C. Jordan, MD

Director, HLA and Transplant Immunology Laboratory, Comprehensive Transplant Center

Director, Division of Nephrology

Director, Nephrology

Medical Director, Kidney Transplant Program, Comprehensive Transplant Center

Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory

Medical Director, Kidney Transplant Program

Professor, Medicine

  • IM/Nephrology
  • Peds - Nephrology
  • Transplant Nephrology
  • Medical School: University of North Carolina, 1973
  • Internship: UCLA, 1974
  • Residency: UCLA, 1976
  • Outstanding Clinical Investigator Award, Western Society for Clinical Investigation, 2016
  • Prize for Research In Scientific Medicine (PRISM), 2015
  • Pioneer in Medicine Award, 2015
  • National Kidney Foundation Gift of Life Award, 2006
  • UCLA Alumni Association Medical Science Award, 2006
  • Toyoda M, Moudgil A, Warady BA, Puliyanda DP, Jordan SC: Clinical significance of peripheral blood Epstein-Barr viral load monitoring using polymerase chain reaction in renal transplant recipients. Pediatric transplantation, , 2008
  • Vo AA, Lukovsky M, Toyoda M, Wang J, Reinsmoen NL, Lai CH, Peng A, Villicana R, Jordan SC: Rituximab and intravenous immune globulin for desensitization during renal transplantation. N. Engl. J. Med., 359(3): 242-51, 2008
  • Vo AA, Wechsler EA, Wang J, Peng A, Toyoda M, Lukovsky M, Reinsmoen N, Jordan SC: Analysis of subcutaneous (SQ) alemtuzumab induction therapy in highly sensitized patients desensitized with IVIG and rituximab. Am. J. Transplant., 8(1): 144-9, 2007

English

Make an Appointment

Call

1-800-CEDARS-1

(1-800-233-2771)

Available 24 Hours A Day

or

Many of the physicians who have medical staff privileges to practice medicine at Cedars-Sinai Medical Center are independent physicians, and not employees or agents of the hospital. These independent physicians bill separately for their services. You should contact your physician to determine their status and billing practices.